ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO885

Donor-Derived Cell-Free DNA in Renal Transplant Recipients with Delayed Graft Function

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Maw, Thin Thin, Keck School of Medicine USC, Los Angeles, California, United States
  • Bromberg, Jonathan, University of Maryland, Baltimore, Maryland, United States
  • Yee, Jim, CareDx, Pasadena, California, United States
  • Gillespie, Matthew, CareDx, Pasadena, California, United States
  • Brennan, Daniel C., Johns Hopkins, Baltimore, Maryland, United States

Delayed graft function (DGF) is a major barrier to improved outcomes after kidney transplantation (KTx) with no definitive tool available to assess severity or chances for recovery. Donor-derived cell-free DNA (dd-cfDNA) was previously validated to discriminate active rejection in KTx pts but its characteristics have not been defined in those with/at risk for DGF. This report describes dd-cfDNA levels in a cohort of KTx pts with suspected DGF.


dd-cfDNA samples of KTX pts with suspected DGF at three centers were obtained between Days 1-16 post-tx as part of the Donor-derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study. Similar clinical data were collected at each sample visit during this early post-tx period as was collected during later visits per DART protocol.


dd-cfDNA samples were obtained from 17 KTx pts with suspected DGF. All received a deceased donor KTx (mean CIT 23 ±9 hours; mean KDPI 64 ±17). Mean dd-cfDNA level was 1.47% (SD 2.25%) in samples collected Days 1-16 post-tx and 0.60% (SD 0.99%) in samples collected at Months 1-24 post-tx. By comparison, the mean level in a reference cohort without DGF from DART was 0.34% (SD 0.58%) in samples collected 30 or more days post-tx. No obvious correlation was seen between Scr and dd-cfDNA in samples from Days 1-16 (Fig. 1) or in Months 1-24 (Fig. 2).


dd-cfDNA levels are higher early post-tx in suspected DGF samples vs. later time points and in those without DGF. Larger studies with long-term follow-up are needed comparing dd-cfDNA levels directly in pts with vs. without DGF after KTx. This may allow for more accurate assessment of dd-cfDNA patterns related to DGF severity/recovery.


  • Commercial Support